Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has provided an announcement.
Clarity Pharmaceuticals has announced its upcoming Annual General Meeting (AGM) scheduled for November 25, 2025. The meeting will provide an opportunity for shareholders to hear about the company’s performance over the past year and vote on various resolutions. Shareholders are encouraged to participate either in person or via teleconference, although remote attendees will not be able to vote. The executive team, led by Dr. Alan Taylor, will report on the company’s progress and future plans, with directors recommending a favorable vote on all resolutions.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals is a clinical stage radiopharmaceutical company that focuses on developing innovative treatments for serious diseases. The company specializes in Targeted Copper Theranostics using its SAR Technology Platform, primarily targeting cancer treatments.
Average Trading Volume: 3,601,451
Technical Sentiment Signal: Buy
Current Market Cap: A$1.82B
See more data about CU6 stock on TipRanks’ Stock Analysis page.